Modern possibilities of torasemide application in clinical practice

Cover Page

Cite item

Full Text

Abstract

Torasemide is a representative of a new generation of loop diuretics, which shows high efficacy and safety in the treatment of patients with heart failure and arterial hypertension. This drug does not only affect the symptoms, but also intervenes in the pathogenesis of cardiovascular disease continuum, improves the quality of life and the prognosis of cardiac patients. The clinical studies showed the efficacy and good tolerability of Trigrim® (local drug torasemide) which could be widely recommend in the treatment of patients with arterial hypertension, edema syndrome, and in presence of chronic heart failure.

About the authors

G. A Batishcheva

Voronezh State Medical University of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., зав. каф. клинической фармакологии ФГБОУ ВО «ВГМУ им. Н.Н.Бурденко». 394036, Russian Federation, Voronezh, ul. Studencheskaia, d. 10

O. A Mubarakshina

Voronezh State Medical University of the Ministry of Health of the Russian Federation

Email: mubarakshina@mail.ru
канд. мед. наук, ассистент каф. клинической фармакологии ФГБОУ ВО «ВГМУ им. Н.Н.Бурденко» 394036, Russian Federation, Voronezh, ul. Studencheskaia, d. 10

M. N Somova

Voronezh State Medical University of the Ministry of Health of the Russian Federation

Email: somova_marina@inbox.ru
канд. мед. наук, доц. каф. клинической фармакологии ФГБОУ ВО «ВГМУ им. Н.Н.Бурденко» 394036, Russian Federation, Voronezh, ul. Studencheskaia, d. 10

A. S Evstigneeva

Voronezh State Medical University of the Ministry of Health of the Russian Federation

клин. ординатор каф. клинической фармакологии ФГБОУ ВО «ВГМУ им. Н.Н.Бурденко» 394036, Russian Federation, Voronezh, ul. Studencheskaia, d. 10

References

  1. Withering W. An acconnt ot the fox - glove and some of its medical uses; with practical remarks of dropsy and other diseases. Birmingham, 1885.
  2. Hutchen D.E, Mehta D, Romano A. Diuretic action of furosemide. Arch Intern Med 1965; 115: 542.
  3. Saxl P, Heiling R. Uber die diuretiche Wircung von Novasurol und anderen Quecksiberinjektionen. Wein Klin Wochenschr 1920; 33: 943.
  4. Roush G.C, Kaur R, Ernst M.E. Diuretics: a review and update. J Cardiovasc Pharmacol Ther 2014; 19 (1): 5-13.
  5. Метелица В.И. Справочник по клинической фармакологии сердечно - сосудистых лекарственных средств. М.: МИА, 2005.
  6. Мареев В.Ю., Выгодин В.А., Беленков Ю.Н. Диyретическая терапия Эффективными дозами пероральных диуретиков торасемида (диувера) и фуросемида в лечении больных с обострением Хронической Сердечной Недостаточности (ДУЭЛЬ - ХСН). Сердечная недостаточность. 2011; 12 (3): 3-10.
  7. Преображенский Д.В., Некрасова Н.И., Талызина И.В., Патарая С.А. Торасемид - петлевой диуретик нового поколения: особенности фармакологии и клиническая эффективность при сердечной недостаточности. Сердечная недостаточность. 2010; 11 (5): 294-300.
  8. Rosón M, Cavallero S, Della Penna S et al. Acute sodium overload produces renal tubulointerstitial inflammation in normal rats. Kidney Int 2006; 70 (8): 1439-46.
  9. Claxton A.J, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-10.
  10. Goodfriend T.L, Ball D.L, Oelkers W et al. Torasemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): L45-50.
  11. Yamato M, Sasaki T, Honda K et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circulat J 2003; 67 (Suppl. 5): 384-90.
  12. Goodfriend T.L, Ball D.L, Oelkers W et al. Torasemide inhibits aldosterone secretion in vitro. Life Sci 1998; 63 (3): L45-50.
  13. Cosin J, Diez J. and TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002; 4 (Suppl. 4): 507-13.
  14. Murray M, Deer M, Ferguson J et al. Open - label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; 111 (Suppl. 7): 513-20.
  15. Spannheimer A, Muller K, Falkenstein P et al. Long - term diuretic treatment in heart failure: are there differences between furo - semide and torasemide? Schweiz Rundsch Med Prax 2002; 91 (Suppl. 37): 1467-75.
  16. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV - efficacy and quality of life. Eur J Heart Fail 2003; 5 (Suppl. 6): 793-801.
  17. Balsam P, Ozierański K, Tymińska A et al. The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial. Trials 2017; 18 (1): 36.
  18. Han L.N, Guo S.L, Lin X.M et al. Torasemide reduces dilated cardiomyopathy, complication of arrhythmia, and progression to heart failure. Genet Mol Res 2014; 13 (3): 7262-74.
  19. Knauf H, Mutschler E, Velazquez H, Giebisch G. Tora semide significantly reduces thiazide - induced potassium and magnesium loss despite supra - additive natriuresis. Eur J Clin Pharmacol 2009; 65: 465-72.
  20. Porcellati C, Verdecchia P, Schillaci G et al. La torasemide, nuovo diuretico del’ansa, nell trattamento dell’ipertensione ar - teriosa: Studio con trolla to in doppla cecita. Bas Razion Terapia 1990; 20: 407-10.
  21. Baumgart P, Walger P, von Eiff M, Achhammer I. Long - term efficacy and tolerance of torasemide in hypertension. In: Progress in pharmacology and Clinical Pharmacology. Stuttgart: Gustav - Fischer - Verlag, 1990; 8: 169-81.
  22. Boelke T, Piesche L. Influence of 2,5-5 mg torasemide o.d. versus 25-50 mg HCTZ/50-100 triamterene o.d. on serum parameters in elderly patients with mild to moderate hypertension. In: Diuretics IV: Chemistry, Pharmacology and clinical Applications. Amsterdam: Excerpta Medica, 1993; p. 279-82.
  23. Achhammer I, Eberhard R. Comparison of serum potassium levels during long - term treatment of hypertension patients with 2,5 mg torasemide o.d. or 50 mg triamterene/25 mg hydrochlorothi - azide o.d. In: Progress in Pharmacology and Clinical Pharmacology. Stuttgart: Gustav-Fischer-Verlag, 1990; 8: 211-20.
  24. Теблоев К.И., Евдокимова А.Г., Ложкина М.В., Евдокимов В.В. Современные возможности оптимизации лечения больных АГ и ХСН при применении торасемида. РМЖ. 2013; 27: 1388.
  25. Свиряев Ю.В., Звартау Н.Э., Коростовцева Л.С. и др. Сравнительная оценка эффективности и безопасности Тригрима и Арифона Ретард у больных с арТериальной гипертонией в слепом рандомизированном исследовании в параллельных группах (исследование СТАРТ). Сердце. 2014; 13 (6): 389-95.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies